Jaguar Health Inc (NASDAQ:JAGX) Expected to Announce Earnings of -$0.24 Per Share

Share on StockTwits

Analysts expect Jaguar Health Inc (NASDAQ:JAGX) to post ($0.24) earnings per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Jaguar Health’s earnings. The highest EPS estimate is ($0.19) and the lowest is ($0.28). The company is scheduled to announce its next earnings results on Wednesday, April 8th.

According to Zacks, analysts expect that Jaguar Health will report full-year earnings of ($5.68) per share for the current fiscal year, with EPS estimates ranging from ($5.99) to ($5.12). For the next financial year, analysts forecast that the firm will report earnings of ($1.22) per share, with EPS estimates ranging from ($2.39) to ($0.67). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that cover Jaguar Health.

Several brokerages have issued reports on JAGX. Zacks Investment Research downgraded shares of Jaguar Health from a “hold” rating to a “sell” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $3.00 target price (down previously from $10.00) on shares of Jaguar Health in a research note on Monday, November 18th. LADENBURG THALM/SH SH assumed coverage on Jaguar Health in a report on Thursday, September 12th. They set a “buy” rating and a $5.00 price target on the stock. Finally, ValuEngine upgraded Jaguar Health from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th.

An institutional investor recently bought a new position in Jaguar Health stock. Wedbush Securities Inc. purchased a new position in shares of Jaguar Health Inc (NASDAQ:JAGX) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 25,100 shares of the biotechnology company’s stock, valued at approximately $33,000. Wedbush Securities Inc. owned 0.05% of Jaguar Health at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.18% of the company’s stock.

JAGX stock traded down $0.04 on Friday, hitting $0.61. The company’s stock had a trading volume of 6,039 shares, compared to its average volume of 1,091,248. The stock has a market cap of $31.20 million, a price-to-earnings ratio of 0.00 and a beta of 0.68. The firm has a 50 day moving average of $0.70 and a two-hundred day moving average of $1.80. The company has a current ratio of 0.88, a quick ratio of 0.61 and a debt-to-equity ratio of 0.61. Jaguar Health has a 1 year low of $0.56 and a 1 year high of $36.39.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc, focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas.

Recommended Story: Roth IRA

Get a free copy of the Zacks research report on Jaguar Health (JAGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jaguar Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Analysts Set $33.00 Target Price for SpringWorks Therapeutics
Ardelyx Inc  Given Consensus Rating of “Hold” by Analysts
Ardelyx Inc Given Consensus Rating of “Hold” by Analysts
Western Midstream Partners LP  Receives $32.25 Consensus Price Target from Analysts
Western Midstream Partners LP Receives $32.25 Consensus Price Target from Analysts
SL Green Realty Corp  Receives $93.85 Average Price Target from Brokerages
SL Green Realty Corp Receives $93.85 Average Price Target from Brokerages
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
HC Wainwright Reaffirms Buy Rating for Y-mAbs Therapeutics
Analysts Set SS&C Technologies Holdings, Inc.  Price Target at $65.91
Analysts Set SS&C Technologies Holdings, Inc. Price Target at $65.91


© 2006-2019 Ticker Report